New: 2+ Hours Saved Daily for Multi-Provider Practices→ Read More
Find comprehensive information on Bone Marrow Transplantation (BMT), also known as Stem Cell Transplantation, for healthcare professionals. This resource covers clinical documentation, medical coding, and BMT diagnosis guidelines. Learn about bone marrow transplant procedures, donor matching, graft-versus-host disease (GVHD), and post-transplant care. Explore relevant medical coding terms and best practices for accurate documentation in bone marrow transplantation.
Also known as
Bone marrow transplant status
Indicates a patient's status post bone marrow transplant.
Diseases of white blood cells
Covers conditions often treated with bone marrow transplant.
Malignant neoplasms of lymphoid, hematopoietic and related tissue
Includes cancers frequently requiring bone marrow transplant.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the transplant autologous (from the patient)?
When to use each related code
| Description |
|---|
| Bone marrow transplant |
| Stem cell transplant |
| Peripheral blood stem cell transplant |
Incorrect coding for allogeneic, autologous, or syngeneic stem cell sources can lead to claim denials and inaccurate reporting.
Failing to capture GVHD as a complication of BMT can impact reimbursement and quality metrics. Proper coding of acute vs chronic GVHD is crucial.
Inaccurate or missing codes for the myeloablative or non-myeloablative conditioning regimen can affect DRG assignment and payment.
Q: What are the most effective pre-transplant conditioning regimens for allogeneic bone marrow transplantation in adult patients with acute myeloid leukemia?
A: Pre-transplant conditioning regimens for allogeneic bone marrow transplantation (BMT) in adult AML patients aim to eradicate leukemia cells, suppress the immune system to prevent graft rejection, and create space in the bone marrow for donor stem cells. Myeloablative conditioning, using high-dose chemotherapy with or without total body irradiation (TBI), remains a standard approach for many patients. Reduced-intensity conditioning (RIC) regimens, utilizing lower doses of chemotherapy and/or TBI, are increasingly used, especially for older patients or those with comorbidities, offering potentially lower toxicity. The choice between myeloablative and RIC depends on factors such as patient age, disease risk, comorbidity burden, and donor characteristics. Specific regimens vary, but commonly involve combinations of fludarabine, busulfan, melphalan, and/or TBI. Explore how patient-specific factors influence conditioning regimen selection and consider implementing strategies to minimize treatment-related toxicity. Learn more about emerging conditioning strategies utilizing targeted therapies or novel agents.
Q: How can Graft-versus-Host Disease (GvHD) be effectively managed and mitigated following allogeneic stem cell transplantation (BMT) for hematological malignancies?
A: Graft-versus-Host Disease (GvHD) is a serious complication of allogeneic stem cell transplantation (also known as bone marrow transplantation or BMT) where donor T cells attack the recipient's tissues. Prophylaxis strategies typically involve immunosuppressants like calcineurin inhibitors (e.g., tacrolimus, cyclosporine) combined with methotrexate or mycophenolate mofetil. GvHD is graded based on severity (acute vs. chronic and grades I-IV), and treatment depends on the presentation and grade. First-line therapy for acute GvHD commonly involves corticosteroids. Second-line options include agents like infliximab, etanercept, or ruxolitinib. Chronic GvHD management is more complex and may necessitate long-term immunosuppression, topical therapies, and supportive care tailored to the affected organs. Consider implementing a multidisciplinary approach involving specialists in dermatology, gastroenterology, pulmonology, and ophthalmology to optimize patient outcomes. Learn more about emerging strategies in GvHD management, including novel immunosuppressants and cellular therapies.
Patient presents for bone marrow transplant evaluation and management of [underlying disease, e.g., acute myeloid leukemia, multiple myeloma, aplastic anemia]. Patient history includes [relevant past medical history, e.g., prior chemotherapy regimens, radiation therapy, relevant comorbidities]. Physical examination reveals [relevant physical findings, e.g., pallor, petechiae, hepatosplenomegaly, lymphadenopathy]. Diagnostic workup including [relevant laboratory tests, e.g., complete blood count with differential, bone marrow biopsy and aspirate, HLA typing, chimerism studies] confirms the diagnosis and indicates eligibility for bone marrow transplantation. The patient's disease status is classified as [disease stage, e.g., first remission, second remission, relapse]. Discussion regarding allogeneic bone marrow transplant, autologous bone marrow transplant, and potential complications such as graft versus host disease, veno-occlusive disease, and infection was conducted. The patient understands the risks and benefits and has opted for [allogeneic or autologous] bone marrow transplantation. A conditioning regimen consisting of [specific chemotherapy andor radiation therapy regimen, e.g., myeloablative conditioning with busulfan and cyclophosphamide, reduced-intensity conditioning with fludarabine and melphalan] is planned. Donor selection and HLA matching are [status of donor selection and HLA matching, e.g., complete, pending, identified sibling donor, unrelated donor search initiated]. Supportive care measures including prophylactic antibiotics, antiviral medications, and blood product transfusions will be implemented. Post-transplant monitoring will include frequent complete blood counts, chimerism studies, and assessment for graft versus host disease. Bone marrow transplant aftercare instructions and follow-up appointments were discussed and scheduled. ICD-10-CM codes for the underlying disease and bone marrow transplantation (e.g., Z94.81, 382.00) are documented.